Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of propranolol in resisting coronavirus infection

A coronavirus and propranolol hydrochloride technology, applied in the field of biomedicine, can solve problems such as lack of propranolol, achieve the effect of preventing and resisting viral infection, reducing viral load, and alleviating disease

Pending Publication Date: 2022-07-15
高银华
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, information on whether propranolol can act on SARS-CoV-2 is still lacking

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of propranolol in resisting coronavirus infection
  • Application of propranolol in resisting coronavirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] (1) Seed 293T cells in a 6-well plate at 37°C, 5% CO 2 Incubate overnight in a cell incubator, and start transfection after the cell density reaches 70% to 90%. The SARS-CoV-2 pseudovirus S protein particles were transfected into 293T cells using Lipofectamine 3000 reagent. 48h after transfection, cells were collected, and the expression of spike protein was detected by Western blot and flow cytometry, respectively, referring to the methods described in related literature.

[0034] (2) Prepare a solution of propranolol and its derivatives or pharmaceutically acceptable salts thereof, whose storage concentration is 1 μM to 100 μM, as a test solution.

[0035] (3) Apply the cell culture medium containing the prepared test solution to the 293T cells before and after transfection in (1) respectively, continue to culture the cells for 24-72 hours, collect the cell supernatant of the experimental group and the control group, and lyse the cells at the same time , RNA was ext...

Embodiment 2

[0038] (1) Seed 293T cells in a 6-well plate at 37°C, 5% CO 2 Incubate overnight in a cell incubator, and start transfection after the cell density reaches 70% to 90%. The SARS-CoV-2 pseudovirus S protein particles were transfected into 293T cells using Lipofectamine 3000 reagent. 48h after transfection, cells were harvested.

[0039] (2) Prepare PBS buffer: first weigh 8.0g NaCl, 0.2g KCl, 1.44g Na 2 HPO 4 , 0.24g KH 2 PO 4 Dissolve in 800 mL of distilled water, then adjust the pH to 7.35 with HCl, and finally add distilled water to dilute to 1 L to obtain 0.01 M, pH 7.4 PBS buffer.

[0040] (3) Prepare a solution of propranolol and its derivatives or its pharmaceutically acceptable salts, whose storage concentration is 1 μM to 100 μM, as test solution A;

[0041] (4) Select other representative anti-new coronavirus drugs, such as FDA-approved drugs (such as Remdesivir, Molnupiravir or Paxloivid) or drugs that have entered the late clinical stage (such as Ensitrelvir or...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of propranolol and derivatives or pharmaceutically acceptable salts thereof in preparation of drugs for preventing or treating coronavirus infection. Researches show that propranolol can effectively inhibit or degrade virus replication organelles and inhibit virus replication, has clear and remarkable prevention and resistance effects on coronaviruses including SARS-CoV-2, SARS-CoV and MERS-CoV, and can relieve various diseases caused by new coronavirus sequelae. Meanwhile, the invention also discloses application of propranolol and the derivatives thereof or pharmaceutically acceptable salts thereof in preparation of medicines for preventing or treating coronavirus infection in combination with other anti-new coronavirus medicines, including anti-new coronavirus medicines which are approved to appear on the market or enter clinic. After combined use, the virus load can be obviously reduced at a low dosage. The invention has important application and popularization significance on the treatment and prevention and control of the current novel coronavirus COVID-19.

Description

technical field [0001] The invention belongs to the technical field of biomedicine. More specifically, it relates to the application of propranolol and its derivatives or pharmaceutically acceptable salts thereof in anti-coronavirus infection, especially in anti-coronavirus (SARS-CoV-2) infection. Background technique [0002] Coronaviruses are a class of enveloped single positive-stranded RNA viruses that can widely exist in humans and other mammals as well as birds, and cause respiratory, digestive, liver and nervous system diseases. Since December 2019, a series of cases of pneumonia of unknown cause have appeared, and the clinical manifestations are very similar to viral pneumonia. Scientists have shown through deep sequencing analysis that there is a new type of coronavirus, which WHO tentatively named 2019 novel coronavirus (2019- nCoV), and then the International Committee on Taxonomy of Viruses (ICTV) announced that the official classification of the new coronavirus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/138A61K45/06A61P31/14
CPCA61K31/138A61K45/06A61P31/14
Inventor 高银华王一
Owner 高银华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com